Clinical Trials Browser

Recurrence, Endometrial Neoplasms

Adenocarcinoma of Endometrium

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Neoplasm Metastasis, Sarcoma, Ewing

Ovarian Neoplasms

Endometrial Neoplasms

Malignant Neoplasms of Female Genital Organs

Breast Neoplasms, Neoplasm, Residual

Breast Neoplasms

Brain Neoplasms, Neoplasm Metastasis

Liver Metastases From Colorectal Cancer (mCRC)

Anatomic Stage III Breast Cancer AJCC v8

Prostatic Neoplasms

Breast Neoplasms

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Endometrial Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

ER-Positive Breast Cancer

Neoplasm Metastasis

Breast Neoplasms

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Breast Neoplasms

Breast Neoplasms, Male

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Breast Neoplasms

Breast Cancer Metastatic

Breast Neoplasms

Small Cell Lung Carcinoma

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

Glioblastoma

Anatomic Stage I Breast Cancer AJCC v8

Breast Neoplasms

Breast Neoplasms

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

Brain Neoplasms, Glioblastoma

Glioblastoma

Advanced Breast Cancer

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Chondrosarcoma, Retinoblastoma, Sarcoma, Osteosarcoma

Breast Neoplasms

Ovarian Neoplasms, Endometrial Neoplasms

Liposarcoma, Sarcoma

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Breast Neoplasms

Breast Neoplasms

Clinical Trials

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

I-SPY

Abemaciclib in Newly Diagnosed Meningioma Patients

CARABELA

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

BOUQUET

Abemaciclib and Letrozole to Treat Endometrial Cancer

Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

MiRaDoR

VIOLET

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Abemaciclib With or Without Atezolizumab for mCRPC

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

TAPUR

ALPINE: Maintenance Letrozole/Abemaciclib

EVOLVE-BDT

Next MONARCH 1

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

GERTRUDE

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

ETHAN - ET for Male BC

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

ARCHE

ABIGAIL

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

ABBICAR

A Study of Abemaciclib in Recurrent Glioblastoma

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

Abemaciclib + Pembrolizumab In Glioblastoma

HERMIONE-7

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Study of Abemaciclib in Dedifferentiated Liposarcoma

Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

ABBY